drugset / Trial / NCT06676709

Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19

NCT06676709 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study, the effects of IMMUNEPOTENT-CRP (I-CRP), a dialyzable leukocyte extract (DLE) derived from bovine spleen cells, on the levels of key inflammatory cytokines in outpatients with COVID-19 were examined. I-CRP has been previously studied for its ability to regulate the immune system in other conditions, such as cancer and sepsis. Based on its potential to reduce harmful inflammation, the study aimed to determine if similar benefits could be observed in COVID-19 outpatients.

Timeline

Start
2021-04-20
Primary completion
2022-02-03
Completion
2022-03-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject IMMUNEPOTENT-CRP (I-CRP) Peptide — —

Indications